Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 12.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 02.10.2024 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | ion. The information appearing below under Item 4.02 is incorporated herein by reference. Item 3.01 Notice of Delist |
| 08.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 22.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | er to supplement the Company’s disclosure under Item 5.02 of the Original Form 8-K with respect to the compensation term |
| 15.12.2023 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | ion. The information appearing below under Item 4.02 is incorporated herein by reference. Item 4.02 Non-Reliance on |
| 29.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Unternehmen & Branche
| Name | EAGLE PHARMACEUTICALS, INC. |
|---|---|
| Ticker | EGRX |
| CIK | 0000827871 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,9 Mio. USD |
| Beta | 0,31 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2023-06-30 | 10-Q | 64,646,000 | 5,164,000 | 0.39 | 404,822,000 | 252,040,000 |
| 2023-03-31 | 10-Q | 66,305,000 | 5,750,000 | 0.44 | 414,175,000 | 242,845,000 |
| 2022-12-31 | 10-K | 316,610,000 | 35,642,000 | 2.73 | 406,160,000 | 233,560,000 |
| 2022-09-30 | 10-Q | 65,901,000 | -7,131,000 | -0.54 | 386,449,000 | 231,780,000 |
| 2022-06-30 | 10-Q | 74,136,000 | -9,450,000 | -0.74 | 381,756,000 | 237,982,000 |
| 2022-03-31 | 10-Q | 115,874,000 | 44,058,000 | 3.41 | 320,165,000 | 215,960,000 |
| 2021-12-31 | 10-K | 171,546,000 | -8,627,000 | -0.66 | 253,732,000 | 176,453,000 |
| 2021-09-30 | 10-Q | 39,853,000 | -5,622,000 | -0.43 | 256,261,000 | 185,293,000 |
| 2021-06-30 | 10-Q | 48,124,000 | 3,612,000 | 0.27 | 264,242,000 | 194,847,000 |
| 2021-03-31 | 10-Q | 41,249,000 | -421,000 | -0.03 | 259,968,000 | 191,078,000 |
| 2020-12-31 | 10-K | 187,802,000 | 11,989,000 | 0.87 | 253,190,000 | 186,011,000 |
| 2020-09-30 | 10-Q | 49,928,000 | 7,059,000 | 0.51 | 248,161,000 | 172,787,000 |
| 2020-06-30 | 10-Q | 41,938,000 | -256,000 | -0.02 | 256,710,000 | 183,964,000 |
| 2020-03-31 | 10-Q | 46,020,000 | -2,871,000 | -0.21 | 361,944,000 | 181,830,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.